Core Concepts
Early diagnosis and intensive treatment are crucial for patients with homozygous familial hypercholesterolemia to prevent premature death.
Abstract
The content highlights the alarming mortality rates among patients with homozygous familial hypercholesterolemia (HoFH) and emphasizes the importance of early diagnosis and aggressive treatment to improve outcomes. Key points include:
Half of HoFH patients die by age 32, with a mean age of diagnosis at 12 years.
Despite treatment, patients had high LDL cholesterol levels, and 70% developed atherosclerotic cardiovascular disease by age 28.
The study underscores the need for a combination of lipid-lowering therapies to reduce cholesterol levels significantly.
Patients with HoFH face severe cardiovascular disease risks, necessitating early intervention and comprehensive treatment strategies.
The findings call for immediate action to improve the diagnosis and management of HoFH to extend patients' lives.
Stats
Half of patients with HoFH die by age 32.
70% of HoFH patients develop atherosclerotic cardiovascular disease by age 28.
Patients receiving treatment had LDL cholesterol levels of 9.4 mmol/L.
Quotes
"Patients with HoFH have severe atherosclerotic cardiovascular disease risk." - Janneke Mulder
"This is something that we should focus on for these patients from the beginning." - Maciej Banach